Navigation Links
Genoptix Announces Participation at the 2010 UBS Global Life Sciences Conference
Date:9/13/2010

CARLSBAD, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the 2010 UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City, to be held September 20-22, 2010.  

President and CEO Tina S. Nova, Ph.D., and Sam Riccitelli, EVP and COO of Genoptix, will present at the conference on Tuesday, September 21, 2010 beginning at noon EDT, when they will provide an overview of the Company's specialized diagnostic laboratory services business, growth strategies and financial performance.

The presentation is expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Genoptix website at www.genoptix.com. Those who would like to listen to the presentation should go to this site at least 15 minutes prior to the event to register, download and install any necessary software. An audio replay will be available for 30 days following the initial presentation webcast.

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports.  Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma, and other forms of cancer. Founded in 1999, Genoptix is a member of the Nasdaq Global Select Market, the S&P SmallCap 600 Index and the Russell 2000 Index and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genoptix, Inc. to Announce First Quarter 2010 Financial Results
2. Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results
3. Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference
4. Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009
5. Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for MPD at 49th Annual American Society of Hematology (ASH) Meeting
6. ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer
7. Sysmex America Announces LabCorp Hematology Automation Agreement
8. K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market
9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
10. Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare
11. Misonix Announces New Distribution Agreement For Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 The National ... health and data analytics company, signed a Memorandum ... improving healthcare delivery in the region. ... Global Health Research and Technology (BIGHEART) at NUS ... several topics related to healthcare IT and medical ...
(Date:3/27/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, ... and efficacy studies. The company is harnessing the power ... MAGE A, in an effort to find a better ... After 4 weeks of treatment in transgenic mice, the ... in a full toxicology report of various organs. Cytotoxic ...
(Date:3/27/2017)... 27, 2017  Sanderling Ventures, portfolio company, Torax ... division of Johnson & Johnson. Torax manufactures and markets ... of gastro-esophageal reflux disease (GERD). The LINK device ... and the procedure is currently available in the ... Medical was founded by Sanderling Ventures, Mayo Medical ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 28, 2017 , ... Qualidigm , the mission-driven national ... a new, more expansive office space in order to accommodate its growing number ... office building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of corrosive ions found in power plant water and steam. , Chlorides and ... turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions ...
(Date:3/28/2017)... ... 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics ... in the country to sit on the 2017 National Advisory Board for Allergan’s Facial ... Dr. Harper helped propel the clinic from a small start-up to number 78 in ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System ... procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. ...
(Date:3/28/2017)... ... 28, 2017 , ... With expansion and efficiency in mind, Patten Seed Company ... seed processing plant opened in Marshallville in 2006, and a bagging and shipping facility ... for transition of Patten Seed operations to the Middle Georgia location from their previous ...
Breaking Medicine News(10 mins):